Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease closely associated with central obesity, dyslipidemia, insulin resistance and diabetes. This disease starts from simple steatosis and can progress through nonalcoholic steatohepatitis (NASH) to fetal fibrosis, cirrhosis and hepatocyte carcinoma.
KBI has developed the NHP models of NAFLD and NASH with all the pathological hallmarks as seen in humans by feeding the KBI designed high fat diet over 2 years. The monkeys are first screened for obesity, dyslipidemia, insulin resistance, diabetes and hypertension to characterize the stage of their NAFLD (Fig 1). KBI can provide NASH animals at different grades and stages for different needs and designs.